人工肝治疗终末期肝病肝衰竭的MELD预后分析

Analysis of Prognosis on Patients with End-stage Liver Disease Treated by Artificial Liver Support System Using the Criterion of Model End-stage Liver Disease

目的 :通过观察应用终末期肝病模型 (MEL D)对人工肝治疗终末期肝病预后的预测作用 ,探讨其在临床的应用价值及人工肝支持系统在终末期肝病治疗中的效果。方法 :4 3例患者随机分为治疗组与对照组 ,对其进行 MELD评分 ,并对治疗组进行人工肝后评分 ,观察 3个月后的残废率。结果 :治疗组中 4例治疗前 MELD评分大于 4 0分者 ,3个月死亡率为 10 0 % ,17例治疗前评分30～ 4 0分者 3个月死亡率为 5 3% ;对照组中 6例 MELD评分大于 4 0分者 ,3个月死亡率为10 0 % ,16例治疗前评分 30～ 4 0分者 3个月死亡率为 87% ,与治疗组相比 P<0 .0 5。结论 :MELD评分可以引入临床推广应用 ,人工肝治疗 MEL D评分在 30～ 4

Objective To study the practical use of model end stage liver disease(MELD) on clinic and the role of artificial liver support system(ALSS) on end stage liver disease.Methods:43 patients were divided randomly into treatment group and control group,and they were graded with MELD before and after ALSS.The death rate was observed three months later.Results:In the treatment group 4 cases with MELD scored higher than 40 before treatment of ALSS were all dead after 3 months,and 17 cases with MELD scored between 30 and 40 remained a death rate of 53%;In the control group,6 cases with MELD scored higher than 40 were all dead too,and the death rate of 16 cases with MELD scored between 30 and 40 was 87% 3 months later;compared with the treatment group,p<0.05.Conclusions:MELD can be popularized in clinic,and ALSS can be used safely and effectively to treat end stage liver disease with MELD scored between 30 and 40.